Quieffin J, Hunter J, Schechter M T, Lawson L, Ruedy J, Paré P, Montaner J S
St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Chest. 1991 Sep;100(3):624-7. doi: 10.1378/chest.100.3.624.
To describe the frequency of aerosol pentamidine-induced bronchoconstriction, its relationship to non-specific airway responsiveness, and its response to preventive therapy using salbutamol, ipratropium bromide, or sodium cromoglycate.
Consecutive HIV-infected individuals starting prophylactic AP were eligible if they had not been previously treated with this agent. Simple spirometry was performed before and 10 min after a single 60-mg dose given through an ultrasonic nebulizer. Methacholine challenge was performed in all subjects 24 h to four days after the initial AP dose. Subjects with a change in FEV1 (delta FEV1) greater than or equal to 10 percent decrease after the initial AP dose were restudied on three separate occasions (greater than 24 hours apart) after premedication with two puffs of salbutamol (200 micrograms), ipratropium bromide (40 micrograms), or sodium cromoglycate (2 mg), in random order.
Fifty-three subjects were studied. The median delta FEV1 after a single dose of AP was -7.0 percent (range: -47 percent, 1.8 percent). The delta FEV1 following AP was only partially predicted by the degree of nonspecific bronchial responsiveness as measured by a standard methacholine challenge. Age, current smoking, history of asthma, baseline FEV1, or a prior episode of PCP failed to predict the delta FEV1 following AP. Eighteen subjects (34 percent) had a delta FEV1 greater than or equal to 10 percent decrease (median: -17.0 percent). In these subjects, after premedication with salbutamol, ipratropium bromide, and sodium cromoglycate, the median delta FEV1 was 1.0, 0.8, and -9.6 percent, respectively.
Aerosol pentamidine produced a decrease in FEV1 greater than or equal to 10 percent in 34 percent of subjects. This was not accurately predicted by the methacholine response. The bronchoconstriction induced by AP was effectively prevented by either salbutamol or ipratropium, whereas cromoglycate was only partially effective.
描述雾化喷他脒诱发支气管收缩的频率、其与非特异性气道反应性的关系,以及其对使用沙丁胺醇、异丙托溴铵或色甘酸钠预防性治疗的反应。
连续入选开始预防性使用喷他脒的HIV感染个体,前提是他们此前未接受过该药物治疗。通过超声雾化器单次给予60毫克剂量喷他脒之前及之后10分钟进行简易肺量计检查。在初始喷他脒剂量后24小时至4天对所有受试者进行乙酰甲胆碱激发试验。初始喷他脒剂量后第一秒用力呼气量(FEV1)变化(ΔFEV1)下降大于或等于10%的受试者,在分别预先吸入两喷沙丁胺醇(200微克)、异丙托溴铵(40微克)或色甘酸钠(2毫克)后,以随机顺序在三个不同时间点(间隔大于24小时)重新进行研究。
共研究了53名受试者。单次剂量喷他脒后的中位ΔFEV1为-7.0%(范围:-47%,1.8%)。喷他脒后的ΔFEV1仅部分可由标准乙酰甲胆碱激发试验测得的非特异性支气管反应程度预测。年龄、当前吸烟情况、哮喘病史、基线FEV1或既往卡氏肺孢子虫肺炎发作均无法预测喷他脒后的ΔFEV1。18名受试者(34%)的ΔFEV1下降大于或等于10%(中位值:-17.0%)。在这些受试者中,预先使用沙丁胺醇、异丙托溴铵和色甘酸钠后,中位ΔFEV1分别为1.0%、0.8%和-9.6%。
34%的受试者雾化喷他脒后FEV1下降大于或等于10%。这无法通过乙酰甲胆碱反应准确预测。沙丁胺醇或异丙托溴铵可有效预防喷他脒诱发的支气管收缩,而色甘酸钠仅部分有效。